Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...

Granules India said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Swizterland based company, for a total consideration of Rs 192.5 crore (CHF 20 million).

With this acquisition, Granules gains capabilities in high-growth peptide-based therapeutics. It also aims to enter the ...

Senn develops and manufactures, peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services.

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Granules India Limited announces acquisition agreement with Senn Chemicals AG, a Swiss-based CDMO specializing in peptides.

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...

Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

Reports Q4 revenue $170.6M vs. $60M last year. “Protagonist is quickly approaching multiple late-stage transformational events expected in the ...

To that end, here is an updated list of five of the very best companies to invest in for 2025 and well beyond: With over $11 trillion in assets under management, there's no doubt BlackRock is the ...

Selena Gomez and Jennifer Aniston brought their star power together to promote the latest releases from their respective ...